Renoprotective Effect of Telmisartan in Patients with Chronic Kidney Disease

References

• Remuzzi G, Ruggenenti P, Perico N. Chronic renal diseases. Renoprotective benefits of renin-angiotensin system inhibition. Ann Intern Med. 2002; 136: 604–615
   PubMed Web of Science ®Google Scholar
• Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol—Renal. 2002; 283: F861–F872
   PubMed Web of Science ®Google Scholar
• Satoh M, Kashihara N, Yamasaki Y. Renal interstitial fibrosis is reduced in angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol. 2001; 12: 317–322
   PubMed Web of Science ®Google Scholar
• Battershill AJ, Scott LJ. Telmisartan: A review of its use in the management of hypertension. Drugs. 2006; 66: 51–83
   PubMed Web of Science ®Google Scholar
• Vogt L, Navis G, Koster J, Manolis AJ, Reid JL, de Zeeuw D. On behalf of the angiotensin II receptor antagonist telmisartan Micardis in isolated systolic hypertension study group. The angiotensin II receptor antagonist telmisartan reduces urinary albumin excretion in patients with isolated systolic hypertension: Results of a randomized, double-blind, placebo-controlled trial. J Hypertens. 2005; 23: 2055–2061
   PubMed Web of Science ®Google Scholar
• Weinbergova O, Metelka R, Vymetal J, Knocny K, Kosatikova Z. Telmisartan in the treatment of hypertension in patients with chronic renal insufficiency. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2004; 148: 69–73
   PubMedGoogle Scholar
• Tomino Y, Suzuki S, Azushima C, Shou I, Iijima T, Yagame M, et al. J Clin Lab Anal. 2001; 15: 188–192
   PubMed Web of Science ®Google Scholar
• Io H, Hamad C, Fukui M, Horikoshi S, Tomino Y. Relationship between levels of urinary type IV collagen and renal injuries in patients with IgA nephropathy. J Clin Lab Anal. 2004; 18: 14–18
   PubMed Web of Science ®Google Scholar
• Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirat Y, Ishimitsu T, et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: A multicenter trial. J Lab Clin Med. 2005; 145: 125–133
   PubMed Web of Science ®Google Scholar
• Kamijo-Ikemori A, Sugaya T, Kimura K. Urinary fatty acid binding protein in renal disease. Clin Chim Acta. 2006, Jun 3 [E-pub ahead of print].
   PubMed Web of Science ®Google Scholar
• Lentine K, Wrone EM. New insights into protein intake and progression of renal disease. Curr Opin Nephrol Hypertens. 2004; 13: 307–312
   PubMed Web of Science ®Google Scholar
• Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem. 2006; 284: 175–182
   PubMed Web of Science ®Google Scholar
• Kurtz TW. New treatment strategies for patients with hypertension and insulin resistance. Am J Med. 2006; 119(Suppl. 1)S24–S30
   PubMedGoogle Scholar
• Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, et al. Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res. 2006; 72: 184–190
   PubMed Web of Science ®Google Scholar
• Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, de Strihou CVY, Miyata T. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005; 16: 3631–3641
   PubMed Web of Science ®Google Scholar
• Nakamura T, Inoue T, Suzuki T, Kawagoe Y, Ueda Y, Koide H, Node K. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens Res. 2008; 31: 841–850
   PubMed Web of Science ®Google Scholar
• Nakamura T, Inoue T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Node K. Beneficial effects of olmesartan and temocapril on urinary liver-type fatty acid-binding protein levels in normotensive patients with immunoglobin A nephritis. Am J Hypertens. 2007; 20: 1195–1201
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Ueda Y, Koide H, Inoue T, Node K. Azelnidipine reduces urinary protein excretion and urinary liver-type fatty acid binding protein in patients with hypertensive chronic kidney disease. Am J Med Sci. 2007; 333: 321–326
   PubMed Web of Science ®Google Scholar
• Iseki K, Iseki C, Ikemiya Y, Kinjo K, Takeshita S. Risk of developing low glomerular filtration rate or elevated serum creatinine in a screened cohort in Okinawa, Japan. Hypertens Res. 2007; 30: 167–174
   PubMed Web of Science ®Google Scholar
• Peralta CA, Shlipak MG, Wassel-Fyr C, Bosworth H, Hoffman B, Martins S, Oldone E, Goldstein MK. Association of antihypertensive therapy and diastolic hypertension in chronic kidney disease. Hypertension. 2007; 50: 474–480
   PubMed Web of Science ®Google Scholar
• Mazzali M, Jefferson JA, Ni Z, Vaziri ND, Johnson RJ. Microvascular and tubulointerstitial injury associated with chronic hypoxia-induced hypertension. Kidney Int. 2003; 63: 2088–2093
   PubMed Web of Science ®Google Scholar
• Norman JT, Stidwill R, Singer M, Fine LG. Angiotensin II blockade augments renal cortical microvascular pO2 indicating a novel-potentially renoprotective action. Nephron Physiol. 2003; 94: 39–46
   Google Scholar
• Manotham K, Tanaka T, Matsumoto M, Ohse T, Miyata T, Inagi R, et al. Evidence of tubular hypoxia in the early phase in the remnant kidney model. J Am Soc Nephrol. 2004; 15: 1277–1285
   PubMed Web of Science ®Google Scholar
• Aizawa T, Ishizaka N, Kurokawa K, Nagai R, Nakajima H, Taguchi J, Ohno M. Different effects of angiotensin II and catecholamine on renal cell apoptosis and proliferation in rats. Kidney Int. 2001; 59: 645–653
   PubMed Web of Science ®Google Scholar
• D'Amico G, Ferrario F, Rastaldi MP. Tubulointerstitial damage in glomerular diseases. Its role in the progression of renal damage. Am J Kidney Dis. 1995; 26: 124–130
   PubMed Web of Science ®Google Scholar
• Chan LYY, Leung JCK, Tang SCW, Choy CBY, Lai KN. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol. 2005; 16: 2306–2317
   PubMed Web of Science ®Google Scholar
• Arici M, Chana R, Lewington A, Brown J, Brunskill NJ. Stimulation of proximal tubular cell apoptosis by albumin-bound fatty acids mediated by peroxisome proliferator activated-gamma. J Am Soc Nephrol. 2003; 14: 17–27
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sugaya T, Kawagoe Y, Suzuki T, Inoue T, Node K. Effect of pitavastatin on urinary liver-type fatty acid binding protein in patients with non-diabetic mild chronic kidney disease. Am J Nephrol. 2006; 26: 82–86
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Koide H. Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes—Metab Res. 2006; 22: 385–389
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis. Clin Nephrol. 2006; 65: 1–6
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sugaya T, Kawagoe Y, Ueda Y, Osada S, Koide H. Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. Am J Med Sci. 2005; 330: 161–165
   PubMed Web of Science ®Google Scholar
• Sodhi CP, Phadke SA, Batlle D, Sahai A. Hypoxia and high glucose cause exaggerated mesangial cell growth and collagen synthesis: Role of osteopontin. Am J Physiol Renal. 2001; 280: F667–F674
   PubMed Web of Science ®Google Scholar
• Kimura M, Asano M, Abe K, Miyazaki M, Suzuki T, Hishida A. Role of atrophic changes in proximal tubular cells in the peritubular deposition of type IV collagen in a rat renal model. Nephrol Dial Transplant. 2005; 20: 1559–1565
   PubMed Web of Science ®Google Scholar
• Ogawa S, Mori T, Nako K, Kato T, Takeuchi K, Ito S. Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy. Hypertension. 2006; 47: 699–705
   PubMed Web of Science ®Google Scholar
• Sharma AM, Hollander A, Koster J. Efficacy and safety in patients with renal impairment; treated with telmisartan (ESPRIT) Study Group Telmisartan in patients with mild/moderate hypertension and chronic kidney disease. Clin Nephrol. 2005; 63: 250–257
   PubMed Web of Science ®Google Scholar
• Rysava R, Tesar V, Merta M, for the Czech Group for the Study of Glomerulonephritis. Effect of telmisartan on blood pressure control and kidney function in hypertensive, proteiuric patients with chronic kidney disease. Blood Press Monit. 2005; 10: 207–223
   PubMed Web of Science ®Google Scholar
• Weinberg AJ, Zappe DH, Ramadugu R, Weinberg MS. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease. J Hypertens. 2006; 24(Suppl)S95–S99
   PubMedGoogle Scholar